Aquestive Therapeutics vs Alpha Teknova
AQST and TKNO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AQST and TKNO compare
Aquestive Therapeutics and Alpha Teknova are about the same size, with market caps of $449M and $463M.
Alpha Teknova grew revenue faster over the last twelve months (15.4% versus 12.5% for Aquestive Therapeutics).
Alpha Teknova keeps more of each dollar of sales as profit, with a net margin of −34.8% compared with −162% at Aquestive Therapeutics.
Alpha Teknova scores higher on the StockData Score (12 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AQST | TKNO |
|---|---|---|
| Size and price | ||
| Market cap | $449M | $463M |
| Share price | $3.58 | $8.62 |
| Change, 1 year | −35.8% | 87.0% |
| Change, 5 years | −40.0% | −65.5% |
| Beta (5Y) | 1.44 | 1.19 |
| Employees | 147 | 158 |
| StockData Score | ||
| Total score | 3 | 12 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.2× (better) | 10.1× |
| P/B | – | 7.7× |
| FCF yield | −9.1% | −1.4% (better) |
| Fair value | – | $3.45 |
| Margin of safety | – | −150% |
| Growth | ||
| Revenue growth (TTM) | 12.5% | 15.4% (better) |
| Revenue growth, 5Y average | −0.58% | 5.3% (better) |
| Profitability | ||
| Gross margin | 65.3% (better) | 36.4% |
| Operating margin | −114% | −32.7% (better) |
| Net margin | −162% | −34.8% (better) |
| FCF margin | −83.3% | −13.9% (better) |
| Return on equity | – | −24.1% |
| Return on invested capital | – | −25.3% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −5.4× | – |
| Current ratio | 6.12 (better) | 3.56 |
| Altman Z-score | −4.62 | 6.03 (better) |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 57.4% | 17.0% |
| Held by insiders | 3.2% | 1.3% |
| Insider net buying, 12 months | −$2.4M | $144K (better) |
| Short interest, % of float | 24.1% | 2.9% |
Go deeper
- AQST stock overview
- AQST income statement
- AQST valuation and score
- TKNO stock overview
- TKNO income statement
- TKNO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.